SYK INHIBITORS

wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediate...

Full description

Saved in:
Bibliographic Details
Main Authors BLOMGREN, Peter, YANG, Zheng-Yu, ZHAO, Zhongdong, FARAND, Julie, KROPF, Jeffrey, PYUN, Hyung-Jung, VENKATARAMANI, Chandrasekar, DU, Zhimin, SANGI, Michael, LAZERWITH, Scott, E, XU, Jianjun, CHANDRASEKHAR, Jayaraman, NOTTE, Gregory, STEVENS, Kirk, L, MAI, Nicholas, LINK, John, O, LEE, Seung H, WATKINS, William, J, ZIPFEL, Sheila, ZABLOCKI, Jeff, LI, Jiayao, SCHRIER, Adam, J, XIONG, Jinming, KATANA, Ashley, A, CURRIE, Kevin, S, KATO, Darryl, MITCHELL, Scott A, GUERRERO, Juan, A, SCHMITT, Aaron, C, LO, Jennifer
Format Patent
LanguageEnglish
French
German
Published 25.10.2017
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
Bibliography:Application Number: EP20140752974